Skip to main content
. 2019 Apr 26;2019(4):CD004055. doi: 10.1002/14651858.CD004055.pub2

Comparison 35. Oral retinoids: re‐treatment alitretinoin versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Primary: investigator‐rated good/excellent control of symptoms 1   Risk Ratio (M‐H, Random, 95% CI) Totals not selected
1.1 Alitretinoin 30 mg vs placebo 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Alitretinoin 10 mg vs placebo 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Primary: adverse events 10 mg vs placebo 1   Risk Ratio (M‐H, Random, 95% CI) Totals not selected
2.1 Any adverse event 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Treatment‐related adverse event 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Nasopharyngitis 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Influenza 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Erythema 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.6 Eczema 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 Dermatitis 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.8 Dry lips 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.9 Cheilitis 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.10 Dry mouth 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.11 Elevated triglycerides 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.12 High cholesterol 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
2.13 High triglycerides 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Primary: adverse events 30 mg vs placebo 1   Risk Ratio (M‐H, Random, 95% CI) Totals not selected
3.1 Any adverse event 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Treatment‐related adverse event 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Treatment‐related serious adverse event 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Nasopharyngitis 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Rhinitis 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.6 Bronchitis 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 Upper respiratory tract infection 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 Influenza 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.9 Erythema 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.10 Eczema 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.11 Dermatitis 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.12 Dry skin 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.13 Headache 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.14 Dry lips 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.15 Nausea 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.16 Cheilitis 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.17 Dry mouth 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.18 Elevated creatinine 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.19 TSH high 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.20 TSH low 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.21 High cholesterol 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.22 High triglycerides 1   Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]